What is Nucrogene?
Nucrogene is a pharmaceutical company focused on the development, manufacturing, and marketing of specialty generic medicines. Their portfolio spans critical therapeutic areas such as cardiovascular, anti-infective, and anti-inflammatory diseases. The company's strategic objective is to enhance patient quality of life by providing accessible and affordable medications across the United States, Latin America, Europe, and other global markets. Nucrogene emphasizes the creation of high-quality, cost-effective drugs in various dosage forms, including tablets, capsules, liquids, and injectables, driven by a commitment to patient care and continuous improvement.
How much funding has Nucrogene raised?
Nucrogene has raised a total of $25K across 1 funding round:
Debt
$25K
Debt (2021): $25K with participation from PPP
What's next for Nucrogene?
With substantial expansion capital secured at a significant Series B/C stage, Nucrogene is poised for accelerated growth and market penetration. This strategic investment is expected to fuel the scaling of its operations, potentially enabling Nucrogene to broaden its product pipeline, enhance manufacturing capabilities, and expand its international reach. The company's focus on accessible and affordable generic medicines positions it to capitalize on evolving healthcare demands and market opportunities, reinforcing its mission to deliver value to patients and healthcare professionals worldwide.
See full Nucrogene company page
